 protective efficacy recombinant hepatitis vaccine newborn infants hepatitis antigen-positive-hepatitis surface antigen carrier mothers Recombinant hepatitis vaccine safe effective plasma-derived vaccines efficacy prevention perinatal infection endemic area high risk infants antigen-positive-hepatitis surface antigen HBsAg carrier mothers study recombinant vaccine efficacy groups infants infants doses vaccine micrograms surface antigen months age additional high risk infants Group doses vaccine months age infants dose IU hepatitis immunoglobulin birth Sera months age HBsAg anti-HBs months age HBsAg carrier rates Groups Group HBsAg-positive rate HBsAg first months age infants substantial titers anti-HBs months age serious adverse effect vaccination